Orchestra BioMed Holdings (OBIO) Operating Expenses (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Operating Expenses data on file, last reported at $22.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 12.11% year-over-year to $22.2 million in Q1 2026; TTM through Mar 2026 was $87.7 million, a 22.32% increase from a year earlier, with the FY2025 full-year figure at $85.3 million, up 27.41% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.2 million, down from $24.2 million in the prior quarter.
• Over the last five years, Operating Expenses for OBIO reached as high as $24.2 million in Q4 2025 and fell as low as $6.0 million in Q1 2022.
• Historically, Operating Expenses has averaged $15.6 million across 5 years, with a median of $15.0 million in 2024.
• Across the five-year window, Operating Expenses soared 17517.86% in 2022 and gained 12.11% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $10.9 million in 2022, then advanced by 16.58% to $12.7 million in 2023, then surged by 32.86% to $16.9 million in 2024, then surged by 42.72% to $24.2 million in 2025, then dropped by 8.18% to $22.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.2 million in Q1 2026, $24.2 million in Q4 2025, and $21.2 million in Q3 2025.